Anthim Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The anthim market size has grown strongly in recent years. It will grow from $4.3 million in 2025 to $4.63 million in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to bioterrorism preparedness initiatives, government funding for biodefense, proven efficacy of monoclonal antibody therapies, strategic national stockpile programs, regulatory approvals for emergency use.

The anthim market size is expected to see strong growth in the next few years. It will grow to $6.13 million in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to continued biodefense investment, rising focus on pandemic and biosecurity readiness, expansion of emergency response infrastructure, technological advances in antibody production, long term government procurement contracts. Major trends in the forecast period include increased stockpiling of anthrax countermeasures, growing government preparedness programs, rising use of monoclonal antibodies in biodefense, expansion of emergency response treatment protocols, enhanced focus on rapid deployment therapies.

The rising prevalence of bacterial infections is expected to drive the growth of the Anthim market going forward. Bacterial infections are illnesses caused by harmful bacteria that enter the body, multiply, and release toxins. The increase in bacterial infections is driven by factors such as the overuse of antibiotics, increased global travel, urbanization, inadequate hygiene practices, and healthcare-associated infections. Anthim (obiltoxaximab) is used in the treatment of anthrax, a bacterial infection caused by Bacillus anthracis, by neutralizing the anthrax toxin and preventing it from entering cells, thereby reducing its damaging effects. For instance, in December 2023, according to a report published by the World Health Organization (WHO), a Switzerland-based health authority, suspected anthrax cases in Zambia increased from 42 between September 2022 and January 2023 to 684 by November 20, 2023, including four deaths (0.6% case fatality rate), across 44 districts in nine of the country’s ten provinces. Therefore, the rising prevalence of bacterial infections is driving the growth of the Anthim market.

The rising healthcare expenditure is expected to propel the growth of the Anthim market going forward. Healthcare expenditure refers to total spending on medical services, treatments, and healthcare resources by governments, insurers, and individuals to ensure accessible and quality care. Healthcare spending is increasing primarily due to the growing burden of chronic and lifestyle-related diseases. Anthim benefits from rising healthcare expenditure, as increased funding supports wider access to advanced and specialized therapies. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, compared with growth of 0.9% in 2022. Therefore, rising healthcare expenditure is driving the growth of the Anthim market.

The increasing prevalence of chronic diseases is expected to further propel the growth of the Anthim market going forward. Chronic diseases are long-term health conditions that progress gradually and typically persist for many years. The rise in chronic diseases is largely attributed to unhealthy lifestyle factors such as poor dietary habits and lack of physical activity. Anthim supports the management of severe and long-term conditions by offering targeted therapeutic effects that help limit disease progression and improve long-term patient outcomes. For instance, in June 2023, according to the Institute for Health Metrics and Evaluation, a US-based public health research institute, more than half a billion people worldwide were living with diabetes, a number projected to exceed 1.3 billion by 2050. Therefore, the growing burden of chronic diseases is contributing to the expansion of the Anthim market.

Major companies operating in the anthim market are Elusys Therapeutics Inc, Hikma Pharmaceuticals.

North America was the largest region in the anthim market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthim market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anthim market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have moderately affected the anthim market by increasing costs for imported biologic manufacturing components and specialized pharmaceutical equipment. These impacts are most pronounced in government procurement and hospital stockpiling programs across north america and europe. Higher tariffs can influence long term contract pricing for biodefense products. However, they also promote domestic monoclonal antibody manufacturing capacity. This enhances national preparedness and supply chain security.

The anthim market research report is one of a series of new reports that provides anthim market statistics, including anthim industry global market size, regional shares, competitors with a anthim market share, detailed anthim market segments, market trends and opportunities, and any further data you may need to thrive in the anthim industry. This anthim market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anthim is a monoclonal antibody used to treat inhalational anthrax caused by infection with Bacillus anthracis. It works by binding to anthrax toxin, thereby preventing the toxin from entering cells and causing harm.

The main types of Anthim are formulations intended for adults and children. Anthim (obiltoxaximab) is indicated for use in adults as part of a treatment regimen for inhalational anthrax resulting from Bacillus anthracis exposure. The clinical indications include treatment of inhalational anthrax and post-exposure prophylaxis (PEP) for inhalational anthrax in both pediatric and adult populations. The various applications include use in hospitals, drug stores, and other healthcare settings.

The anthim market consists of sales of monoclonal antibodies, injectable solutions and emergency response treatments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.